ArticleUrolithiasis2026
Salidroside attenuates calcium oxalate-induced renal injury via suppression of PANoptosis.
Article in Urolithiasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Natural compounds targeting inflammatory signaling and cell adhesion molecules in ischemic acute kidney injury.Archives of pharmacal research · 2026Review
- Identification of a novel PANoptosis-associated prognostic signature and immune landscape analysis in neuroblastoma with experimental validation.Frontiers in immunology · 2026Article
- Regulated Cell Death in Calcium Oxalate Stone Disease: From Tubular Epithelial Injury to Inflammatory Amplification.Journal of inflammation research · 2026Review
- Recent advances in PANoptosis research in kidney disease: mechanistic networks, pathological roles, and potential intervention strategies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Calcium oxalate (CaOx), the primary constituent of most urinary calculi, triggers inflammatory responses and tissue damage upon entry into renal tubules, playing a pivotal role in nephrolithiasis pathogenesis. Salidroside (SAL), a phenolic glycoside isolated from Rhodiola plants, exhibits diverse pharmacological activities. This study integrated network pharmacology with experimental validation to investigate the therapeutic potential and mechanistic basis of SAL against urinary stones. In both in vitro and in vivo models of CaOx crystal-induced kidney injury, SAL treatment markedly reduced renal crystal deposition, inflammatory cascades, and associated histological impairments. Network pharmacology analysis suggested the involvement of PANoptosis, a finding subsequently confirmed through experimental assays as the central mechanism underpinning SAL-mediated protection. Molecular docking and further experimental verification indicated that SAL directly engages with core components of the PANoptosome complex. These results collectively demonstrate that SAL mitigates nephrolithiasis-related renal injury and inflammation primarily through suppression of PANoptosis.
Indexed as
Identifiers
41483174What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.